The Prolyl Isomerase Pin1 Acts Synergistically with CDK2 to Regulate the Basal Activity of Estrogen Receptor α in Breast Cancer

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Lucchetti, Chiara ^a   Caligiuri, Isabella ^a,b,c   Toffoli, Giuseppe ^d   Giordano, Antonio ^a,b,c   Rizzolio, Flavio ^a,d  

^a Temple University   (United States)

^b Human Health Foundation   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PEPTIDYLPROLYL ISOMERASE PIN1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION REGULATION;

BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTAGENESIS, SITE-DIRECTED; PEPTIDYLPROLYL ISOMERASE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BINDING; SERINE; SIGNAL TRANSDUCTION;

EID: 84873502193     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055355     Document Type: Article

References (53)

1. Hennighausen L, Robinson GW, (2005) Information networks in the mammary gland. Nat Rev Mol Cell Biol 6: 715-725.
2. Caligiuri I, Rizzolio F, Boffo S, Giordano A, Toffoli G, (2011) Critical choices for modeling breast cancer in transgenic mouse models. J Cell Physiol 227: 2988-2991.
3. Ali S, Buluwela L, Coombes RC, (2011) Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu Rev Med 62: 217-232.
4. Rajbhandari P, Finn G, Solodin NM, Singarapu KK, Sahu SC, et al. (2012) Regulation of estrogen receptor alpha N-terminus conformation and function by peptidyl prolyl isomerase Pin1. Mol Cell Biol 32: 445-457.
5. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, et al. (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28: 509-518.
6. McDonnell DP, Norris JD, (2002) Connections and regulation of the human estrogen receptor. Science 296: 1642-1644.
7. Osborne CK, Schiff R, (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62: 233-247.
8. Kumar R, Zakharov MN, Khan SH, Miki R, Jang H, et al. (2011) The dynamic structure of the estrogen receptor. J Amino Acids 2011: 812540.
9. Kumar R, McEwan IJ, (2012) Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr Rev 33: 271-299.
10. Burns KA, Li Y, Arao Y, Petrovich RM, Korach KS, (2011) Selective mutations in estrogen receptor alpha D-domain alters nuclear translocation and non-estrogen response element gene regulatory mechanisms. J Biol Chem 286: 12640-12649.
11. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L, (2005) Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 19: 2671-2684.
12. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, et al. (2001) Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 276: 18375-18383.
13. Williams CC, Basu A, El-Gharbawy A, Carrier LM, Smith CL, et al. (2009) Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC Biochem 10: 36.
14. Zhou XZ, Lu PJ, Wulf G, Lu KP, (1999) Phosphorylation-dependent prolyl isomerization: a novel signaling regulatory mechanism. Cell Mol Life Sci 56: 788-806.
15. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, et al. (1997) Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 278: 1957-1960.
16. Shen M, Stukenberg PT, Kirschner MW, Lu KP, (1998) The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev 12: 706-720.
17. Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP, et al. (2004) Prevalent overexpression of prolyl isomerase Pin1 in human cancers.
18. Khanal P, Namgoong GM, Kang BS, Woo ER, Choi HS, (2010) The prolyl isomerase Pin1 enhances HER-2 expression and cellular transformation via its interaction with mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1. Mol Cancer Ther 9: 606-616.
19. Ryo A, Liou YC, Wulf G, Nakamura M, Lee SW, et al. (2002) PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol 22: 5281-5295.
20. Liou YC, Ryo A, Huang HK, Lu PJ, Bronson R, et al. (2002) Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci U S A 99: 1335-1340.
21. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, et al. (2011) A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20: 79-91.
22. Napoli M, Girardini JE, Piazza S, Del Sal G, (2011) Wiring the oncogenic circuitry: Pin1 unleashes mutant p53. Oncotarget 2: 654-656.
23. Yi P, Wu RC, Sandquist J, Wong J, Tsai SY, et al. (2005) Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1). Mol Cell Biol 25: 9687-9699.
24. Stanya KJ, Liu Y, Means AR, Kao HY, (2008) Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT. J Cell Biol 183: 49-61.
25. Lannigan DA, (2003) Estrogen receptor phosphorylation. Steroids 68: 1-9.
26. Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, et al. (2002) Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera.
27. Bunone G, Briand PA, Miksicek RJ, Picard D, (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15: 2174-2183.
28. Dutertre M, Smith CL, (2003) Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Mol Endocrinol 17: 1296-1314.
29. Vilgelm A, Lian Z, Wang H, Beauparlant SL, Klein-Szanto A, et al. (2006) Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res 66: 3375-3380.
30. Rizzolio F, Lucchetti C, Caligiuri I, Marchesi I, Caputo M, et al. (2012) Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1. Cell Death Differ 19: 1152-1161.
31. Rizzolio F, Pramparo T, Sala C, Zuffardi O, De Santis L, et al. (2009) Epigenetic analysis of the critical region I for premature ovarian failure: demonstration of a highly heterochromatic domain on the long arm of the mammalian X chromosome. J Med Genet 46: 585-592.
32. Roberti A, Rizzolio F, Lucchetti C, De Leval L, Giordano A, (2011) Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines. Cell Cycle 10: 127-134.
33. Lu KP, Liou YC, Zhou XZ, (2002) Pinning down proline-directed phosphorylation signaling. Trends Cell Biol 12: 164-172.
34. Kuntz MA, Shapiro DJ, (1997) Dimerizing the estrogen receptor DNA binding domain enhances binding to estrogen response elements. J Biol Chem 272: 27949-27956.
35. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, et al. (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295: 1658-1667.
36. Ali S, Buluwela L, Coombes RC, (2011) Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annual review of medicine 62: 217-232.
37. Allegra JC, Lippman ME, Simon R, Thompson EB, Barlock A, et al. (1979) Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat Rep 63: 1271-1277.
38. Osborne CK, Yochmowitz MG, Knight WA 3rd, McGuire WL, (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884-2888.
39. Williams MR, Todd JH, Ellis IO, Dowle CS, Haybittle JL, et al. (1987) Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer 55: 67-73.
40. Gray (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
41. Lee KY, Lee JW, Nam HJ, Shim JH, Song Y, et al. (2011) PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells. Mol Cells 32: 107-111.
42. Valley CC, Metivier R, Solodin NM, Fowler AM, Mashek MT, et al. (2005) Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor alpha N terminus. Mol Cell Biol 25: 5417-5428.
43. Sentis S, Le Romancer M, Bianchin C, Rostan M-C, Corbo L, (2005) Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Molecular endocrinology (Baltimore, Md) 19: 2671-2684.
44. Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, et al. (2010) A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer. Endocr Relat Cancer 17: 589-597.
45. Rizzolio F, Caligiuri I, Lucchetti C, Fratamico R, Tomei V, et al. (2012) Dissecting Pin1 and phospho-pRb regulation. J Cell Physiol.
46. Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, et al. (2008) Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 15: 755-763.
47. Jiang J, Sarwar N, Peston D, Kulinskaya E, Shousha S, et al. (2007) Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin Cancer Res 13: 5769-5776.
48. Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, et al. (2006) Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer 13: 851-861.
49. Trowbridge JM, Rogatsky I, Garabedian MJ, (1997) Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proceedings of the National Academy of Sciences of the United States of America 94: 10132-10137.
50. Henry MK, Nimbalkar D, Hohl RJ, Quelle FW, (2004) Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells. Exp Cell Res 299: 257-266.
51. Wierod L, Rosseland CM, Lindeman B, Oksvold MP, Grosvik H, et al. (2007) CDK2 regulation through PI3K and CDK4 is necessary for cell cycle progression of primary rat hepatocytes. Cell Prolif 40: 475-487.
52. Takeda A, Osaki M, Adachi K, Honjo S, Ito H, (2004) Role of the phosphatidylinositol 3′-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 28: 353-358.
53. Liao Y, Wei Y, Zhou X, Yang JY, Dai C, et al. (2009) Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. Oncogene 28: 2436-2445.